Gilead will pay $175 million upfront for Cell Design Labs and will dish out additional payments of up to $322 million if certain milestones are hit.
The acquisition equips Gilead with additional resources to focus on the development of CAR-T cell therapies, which are personalized medications that genetically alter patients’ immune cells to attack cancer.
Cell Design is currently working on a custom cell engineering technology, including early state treatments for prostate cancer, which Gilead hopes to capitalize on.
More articles on supply chain:
Prescription drug spending slows in 2016: 5 things to know
Worsening IV fluid shortage forces New York hospital to transfer patient
FDA urges drugmaker to recall osteoarthritis product following liver and lung injury reports
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
